Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma

NCT05471674 is registered in ClinicalTrials.gov with Dr Tan-to CHEUNG as lead sponsor.

NCT NCT05471674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05471674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Lead sponsor
Dr Tan-to CHEUNG
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2020
Completion date
December 31, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, hepatocellular carcinoma, liver cancer